SeaStar Medical Holding Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ICU research report →
Range $8 – $8
Price Chart
About the company
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome.
- CEO
- Eric Schlorff
- IPO
- 2021
- Employees
- 18
- HQ
- Denver, CO, US
Get TickerSpark's AI analysis on ICU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.65M
- P/E
- -0.29
- PEG
- -0.00
- P/S
- 1.38
- P/B
- 9.83
- EV/EBITDA
- 0.07
- Div Yield
- 0.00%
- Gross Margin
- 92.61%
- Op Margin
- -692.42%
- Net Margin
- -678.24%
- ROE
- -261.10%
- ROIC
- -3196.38%
Latest fiscal year · YoY change
- Revenue
- $1.23M+814.1%
- Gross Profit
- $1.18M+774.8%
- Op Income
- $-12,175,000
- Net Income
- $-12,150,000+51.1%
- EPS
- $-5.86+91.2%
- OCF Growth
- +15.0%
- FCF Growth
- +15.0%
- 52W High
- $5.38
- 52W Low
- $0.76
- 50D MA
- $2.76
- 200D MA
- $3.26
- Beta
- -1.04
- RSI (14)
- 28
- Avg Volume
- 195.25K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
SeaStar posted strong QUELIMMUNE sales growth and encouraging clinical/regulatory progress, but pushed NEUTRALIZE-AKI enrollment timing to mid-2027 and remains cash constrained.· November 11, 2026
- QUELIMMUNE net revenue rose to over $630,000 in Q3, up 247% year over year, and 9-month revenue reached $1.7 million.
- Management said full-year QUELIMMUNE revenue should exceed its $2 million goal, helped by stronger demand and new hospital adoption.
- NEUTRALIZE-AKI is about 75% enrolled at 251 of 339 patients, but completion guidance moved to mid-2027 due to strict eligibility criteria and slower enrollment.
- The FDA granted Breakthrough Device Designation for adult sepsis, and management said sepsis patients could represent more than 70% of the trial population.
- Cash was about $4 million at September 30, 2026, before $3.3 million of gross warrant proceeds received in October.
SeaStar recorded third-quarter 2026 net revenue of approximately $635,000, up 247% from approximately $183,000 in Q3 2025. Gross profit percentage stayed above 90%, consistent with prior quarters this year. Operating expenses were $5.2 million versus $3.7 million a year ago, and net loss was approximately $4.5 million, or $1.03 per share, versus a net loss of approximately $3.5 million, or $1.30 per share, in Q3 2025. QUELIMMUNE 9-month net revenue more than doubled to $1.7 million, and management said it expects to exceed its $2 million full-year revenue guidance. NEUTRALIZE-AKI enrollment has reached 251 of 339 intended patients, and management now anticipates completing enrollment by midyear 2027. Cash was approximately $4 million at September 30, 2026, excluding $3.3 million of gross proceeds from warrant exercises received in October.
Eric Schlorff emphasized that the company is seeing momentum in QUELIMMUNE demand, education efforts, and clinical/regulatory visibility, including the late-breaker presentation of registry data at ASN Kidney Week 2026. He framed the adult AKI program and the new sepsis Breakthrough Device Designation as evidence that the SCD platform may have broader utility across multiple serious inflammatory conditions. His tone was upbeat on the long-term opportunity but cautious on enrollment timing, saying management is “disappointed” to extend the timeline while prioritizing a rigorous study.
Michael Messinger highlighted Q3 revenue of about $635,000, a 247% year-over-year increase, while gross margin remained above 90%. He said operating expenses rose to $5.2 million from $3.7 million, driven mainly by higher R&D tied to NEUTRALIZE-AKI and SCD development, partially offset by lower G&A. He reported net loss of $4.5 million and cash of about $4 million at quarter-end, noting that this excluded $3.3 million of gross warrant-exercise proceeds received in October.
Analysts pressed on the delayed NEUTRALIZE-AKI timeline, with management estimating that final PMA module filing could occur about 9 months after enrollment completion; Eric also noted the FDA typically has 180 days for review, though the modular PMA approach is intended to help shorten the process. Questions also focused on QUELIMMUNE adoption, where management said 20 customers are currently using the product and adoption is still constrained by the ultra-rare nature of the patient population, not lack of interest. On the SAVE registry change, Tim said hospitals have responded positively because removing the mandatory registry requirement should reduce effort and make QUELIMMUNE easier to adopt. For the sepsis Breakthrough Device Designation, management said the trial was prospectively designed with sepsis and ARDS subanalyses and that discussions with the FDA will proceed in parallel as enrollment and analysis advance.
The call showed clear commercial traction, with QUELIMMUNE revenue up sharply year over year, all 20 customers reportedly using the product, and management expecting to exceed full-year revenue guidance. Management also pointed to regulatory tailwinds, including confirmation that the SAVE registry requirement is met and a new Breakthrough Device Designation for adult sepsis, which they believe could broaden the SCD platform’s opportunity.
The biggest risk is timing: NEUTRALIZE-AKI enrollment is slower than hoped, and completion has moved out to mid-2027 because of strict trial criteria. Cash remains limited at about $4 million at quarter-end, and the company is still loss-making with quarterly operating expenses far above revenue. Growth in QUELIMMUNE is also tied to a very small, ultra-rare market, so expansion depends on continued site activation and education rather than broad demand.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.3%
- Shares Outstanding
- 2.84M
- Float Shares
- 2.82M
of shares held by institutions
19 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 377.38K | 0 |
| Lpl Financial LLC | 66.80K | ▲ 66.80K |
| Geode Capital Management, LLC | 51.01K | ▲ 1.42K |
| Vanguard Capital Management LLC | 33.09K | 0 |
| Ubs Group AG | 26.61K | ▼ 4.78K |
| Vanguard Fiduciary Trust Co | 13.69K | 0 |
| Hrt Financial LP | 12.58K | ▲ 12.58K |
| Northern Trust Corp | 10.40K | ▲ 10.40K |
| Pnc Financial Services Group, Inc. | 4.94K | 0 |
| Tower Research Capital LLC (Trc) | 1.36K | ▼ 39 |
| Blackrock, Inc. | 913 | 0 |
| Barclays PLC | 633 | ▲ 629 |
Held by 9 ETFs
Biggest fund positions in ICU by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Messinger Michael | buy | 2,500 |
| Nov 16, 26 | Chung Kevin | buy | 7,800 |
| Aug 18, 26 | Messinger Michael | buy | 750 |
| Jul 1, 26 | Schlorff Eric | other | 10,288 |
| Jul 1, 26 | Chung Kevin | other | 7,202 |
| Jul 1, 26 | Vincent Bernadette N | other | 4,000 |
| Jul 1, 26 | Neuman John | other | 4,000 |
| Jul 1, 26 | Van Heel Kenneth | other | 4,000 |
| Jul 1, 26 | Baird Jennifer A | other | 4,000 |
| Feb 6, 26 | Van Heel Kenneth | other | 3,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ICU coverage
Recent articles, reports, and earnings notes.
No research on ICU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ICU report →ICU Medical to Participate at the Piper Sandler 38th Annual Healthcare Conference
globenewswire.com · Nov 19
SeaStar Medical Holding Corporation (ICU) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 11
SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com · Nov 11
ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London
globenewswire.com · Nov 6
ICU Medical Q3 Earnings Call Highlights
marketbeat.com · Nov 5
SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026
globenewswire.com · Nov 4
Stellantis In The ICU, Struggling To Bounce Back From Financial Collapse
seekingalpha.com · Nov 3
FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients
globenewswire.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.